Clinuvel Pharmaceuticals Limited

As of June 30, 2026, Clinuvel Pharmaceuticals Ltd. carries a market capitalization of 304.18M, placing it among publicly traded companies globally. Its enterprise value stands at 131.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Clinuvel Pharmaceuticals Ltd.'s next confirmed earnings release is scheduled for February 23, 2027.

As of June 30, 2026, Clinuvel Pharmaceuticals Ltd. has 50.43M shares outstanding.

As of June 30, 2026, Clinuvel Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 12.85. The price-to-sales ratio is 4.64, and the price-to-book ratio stands at 1.61.

As of June 30, 2026, Clinuvel Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 4.67 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.79 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 131.09M versus a market cap of 304.18M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Clinuvel Pharmaceuticals Ltd. maintains a current ratio of 14.81, meaning it holds 14.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Ltd. posted a return on equity (ROE) of 13.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.47 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.14, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.01 indicates how many times Clinuvel Pharmaceuticals Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Ltd. recorded 9.51M in income tax expense. That works out to an effective tax rate of 28.84, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 32.98M, leaving 23.47M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Clinuvel Pharmaceuticals Ltd.'s stock has declined approximately 30.69% over the past 52 weeks. The 50-day moving average sits at 7.11, while the 200-day moving average is 10.44.

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Ltd. generated 65.07M in revenue and converted that into 23.47M in net income, yielding earnings per share of 0.46. EBITDA reached 28.05M, while operating income came in at 27.37M.

As of June 30, 2026, Clinuvel Pharmaceuticals Ltd. holds 174.43M in cash and equivalents against 1.34M in total debt, resulting in a net debt position of -174.43M. Total book value stands at 188.85M, with working capital of 183.68M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Ltd. posted a gross margin of 83.18, reflecting its pricing power and cost economics. The operating margin of 42.06 and net profit margin of 36.07 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Ltd. paid dividends of 0.03 per share. The dividend payout ratio of 7.39 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.63, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Clinuvel Pharmaceuticals Ltd. shareholders.

Clinuvel Pharmaceuticals Ltd.'s most recent stock split took place on November 12, 2010 with a 10:1 split ratio.

As of June 30, 2026, Clinuvel Pharmaceuticals Ltd. has an Altman Z-Score of 14.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.